We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
Read MoreHide Full Article
Denmark-based biotech Genmab A/S (GMAB - Free Report) announced that it has initiated a phase III study evaluating the investigational antibody-drug conjugate tisotumab vedotin as compared to chemotherapy for treating recurrent/metastatic cervical cancer in patients who have received one or two prior lines of systemic therapy.
The global, randomized innovaTV 301 study is designed to evaluate the efficacy of tisotumab vedotinas compared with physicians’ choice single agent chemotherapy for the given indication. The study will enroll around 482 cervical cancer patients who have received one or two prior lines of systemic therapy for their metastatic disease. The primary endpoint of the study is overall survival.
Notably, the innovaTV 301 study will serve as a confirmatory study for a potential accelerated approval of tisotumab vedotin in the United States and also support regulatory filings for global marketing approval for recurrent cervical cancer.
Shares of Genmab have surged 90.6% in the past one year compared with the industry’s increase of 5.6%.
Per the company, currently, there is no established standard of care for women with metastatic cervical cancer whose disease has progressed following the first or second line of treatment. As a result, if successfully developed and upon potential approval, tisotumab vedotin can become a safe and effective treatment option for the given patient population.
We note that Genmab is developing tisotumab vedotin in collaboration withSeagenInc. . The companies share all costs and profits equally for the product. The innovaTV 301 study will be sponsored and conducted by Seagen in collaboration with Genmab, European Network of Gynaecological Oncological Trial Groups and the Gynecologic Oncology Group.
Apart from cervical cancer, tisotumab vedotin is being investigated as monotherapy in a range of solid tumors including ovarian cancer and in combination with commonly used therapies for metastatic cervical cancer.
Alkermes’ earnings estimates have been revised 8.3% upward for 2021 over the past 60 days. The stock has increased 1.4% in the past year.
Blueprint Medicines’ loss per share estimates have narrowed 1.6% for 2021 over the past 60 days. The stock has rallied 28.7% in the past year.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
Denmark-based biotech Genmab A/S (GMAB - Free Report) announced that it has initiated a phase III study evaluating the investigational antibody-drug conjugate tisotumab vedotin as compared to chemotherapy for treating recurrent/metastatic cervical cancer in patients who have received one or two prior lines of systemic therapy.
The global, randomized innovaTV 301 study is designed to evaluate the efficacy of tisotumab vedotinas compared with physicians’ choice single agent chemotherapy for the given indication. The study will enroll around 482 cervical cancer patients who have received one or two prior lines of systemic therapy for their metastatic disease. The primary endpoint of the study is overall survival.
Notably, the innovaTV 301 study will serve as a confirmatory study for a potential accelerated approval of tisotumab vedotin in the United States and also support regulatory filings for global marketing approval for recurrent cervical cancer.
Shares of Genmab have surged 90.6% in the past one year compared with the industry’s increase of 5.6%.
Per the company, currently, there is no established standard of care for women with metastatic cervical cancer whose disease has progressed following the first or second line of treatment. As a result, if successfully developed and upon potential approval, tisotumab vedotin can become a safe and effective treatment option for the given patient population.
We note that Genmab is developing tisotumab vedotin in collaboration withSeagenInc. . The companies share all costs and profits equally for the product. The innovaTV 301 study will be sponsored and conducted by Seagen in collaboration with Genmab, European Network of Gynaecological Oncological Trial Groups and the Gynecologic Oncology Group.
Apart from cervical cancer, tisotumab vedotin is being investigated as monotherapy in a range of solid tumors including ovarian cancer and in combination with commonly used therapies for metastatic cervical cancer.
Zacks Rank & Stocks to Consider
Genmab currently carries a Zacks Rank #2 (Buy). Top-ranked stocks in the biotech sector include Alkermes plc (ALKS - Free Report) and Blueprint Medicines Corporation (BPMC - Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ earnings estimates have been revised 8.3% upward for 2021 over the past 60 days. The stock has increased 1.4% in the past year.
Blueprint Medicines’ loss per share estimates have narrowed 1.6% for 2021 over the past 60 days. The stock has rallied 28.7% in the past year.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>